DUBLIN, Dec 17, 2018 /PRNewswire/ --
The "Diabetic Foot Ulcer (DFU) Market & Drug Pipeline Analysis - Forecast to 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.
Diabetic Foot Ulcer (DFU) Pipeline Analysis gives comprehensive insights on the various drugs being developed for the treatment of DFU. The report covers all the drugs that are in various phases of development (Discovery, Preclinical and Clinical).
The pipeline focuses on novel pharmacologic drugs and regenerative medicines covering, antibodies, stem cell therapies, recombinant proteins, Peptide therapies, RNA-based therapeutics and others, but excludes symptom relief drugs, wound dressing, drug delivery systems, generic combinations and radiation therapies. The report also covers some of the hot targets in research for DFU treatments and related biomarkers.
This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the DFU drugs market. The report also provide strategic insights on some of the molecules that are yet to be launched in the next few years.
Some of the key sections covered in the report are given below:
DFU Introduction
DFU grading, Treatment algorithm, Patient care pathway & Visiting patterns, Clinical practice guidelines, Current SOC, Adjuvant therapies, Alternative approaches, Unmet needs, ICD/CPT codes
Epidemiology
Hot Targets, Pathophysiology and Biomarkers
In this section, various DFU associated targets, pathophysiology, and biomarkers are discussed. Also, covers novel targets in early research for DFU.
Market Data
Pipeline Analysis
Pipeline analysis was carried to get deeper insights on various treatment modalities in discovery, preclinical and development section, pipelines from major companies were identified and potential targets were reported along with Mechanism of action, Current development status and nature of molecule. Pipeline analysis by developmental stage (Discovery to Clinical development).
Key Players Analysis
Key Topics Covered:
1 Report Description
2 Summary
3 Introduction
3.1 Epidemiology
3.2 Causes, Symptoms And Risk Factors
3.3 Grading Systems
3.4 Diagnosis And Management
3.5 Algorithm For DFU Treatment
3.6 Care Pathways And Patient Visiting Patterns
3.7 Clinical Practice Guidelines
3.8 Current Standard Of Care
3.9 Adjuvant Therapies
3.10 Alternative Therapeutic Approaches
3.11 Unmet Needs
3.12 ICD/CPT Codes
4 DFU Pathophysiology, Targets And Biomarkers
4.1 Pathophysiology Of DFU
4.2 Leading Targets
4.3 Novel Targets
4.4 Biomarkers
5 Market Data
5.1 Forecasting Model
5.2 Market Dynamics
5.3 Market Sizing
5.4 DFU Deals
5.5 Funding Scenario
5.6 Regulatory Guidelines
5.7 DFU Regulatory Guidelines
6 Pipeline Analysis
6.1 Development Stage
6.2 Molecule Type
6.3 Clinical Update On Phase 3 Molecules
7 Small Molecules
7.1 Pipeline
7.2 Competitive Analysis
8 Large Molecule
8.1 Pipeline
8.2 Competitive Analysis
8.2.1 Stem Cell Therapies
8.2.2 Protein Therapies
8.2.3 Peptide Therapies
8.2.4 Large Molecules (Unspecified)
8.2.5 Other Molecules
9 DFU Drug Analysis Based On Mechanism
10 Major Players
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5lq4gk/global_diabetic?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
These press releases may also interest you
|